Keyword: Seamus Fernandez
As Aclaris Therapeutics goes all-in on its Eskata launch, at least one analyst thinks the rollout could raise eyebrows among investors—in a good way.
Allergan investors fretted Tuesday over strong data from a potential Botox competitor. But the way analysts see it, there’s not much to worry about.
If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.
Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?
Analysts recently sized up Bristol-Myers as a takeover target. Now, word has it that Roche, Novartis and Pfizer are actively looking at a buy. But a megamerger? That's the question.